NAtrol CT/NG external Run Control Negative

https://www.gentaur.be/web/image/product.template/696/image_1920?unique=f55fc04

1628,40 zł 1628.4 PLN 1628,40 zł

345,00 €

Not Available For Sale

    Ta kombinacja nie istnieje.

    Terms and Conditions
    Gwarantowany zwrot pieniędzy przez 30dni
    Wysyłka w ciągu 2-3 dni roboczych

    INTENDED USE: 

    The NATtrol™ Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) Negative Control is an unassayed in vitro diagnostic external run control intended to be used with qualitative molecular assays for detection of nucleic acids from these organisms. The control is intended to be used as an aid to diagnosis in that it is used to verify performance of the assays used to detect a physiological or pathological state. The routine and repetitive use of external run controls enables laboratories to monitor daily test variation, lot-to-lot test kit performance, individual operator variation, and can provide assistance in identifying increases in random or systemic errors. NATtrol™ CT/NG Negative Control contains intact organisms and should be run in a manner identical to that used for clinical specimens. The control does not have an assigned value and it is the responsibility of the end user to establish their own target specifications for the control using their laboratory’s molecular procedures. 



    PRODUCT SUMMARY AND EXPLANATION: 

    Each NATtrol™ CT/NG Negative Control Pack contains 6 x 1.25 mL vials of A-549 cells formulated in a Purified Protein Matrix that is fully commutable with true clinical specimens. 

    Pat.: http://www.zeptometrix.com/patent-information/ 



    PRINCIPLE: 

    NATtrol™ CT/NG Negative Controls contain A-549 cells formulated in a proprietary Purified Protein Matrix that mimics the composition of a true clinical specimen. These are full process controls designed to monitor the effectiveness of extraction, amplification, and detection in nucleic acid testing procedures. These controls are suitable for use in in-house molecular assays and commercially available platforms. 



    PRECAUTIONS: 

    Handling and disposal of NATtrol™ CT/NG Negative Controls should be conducted as if the material is potentially infectious. This control contains material of human and animal origin and the user should observe Universal Precautions when handling and disposing of this product. Disposal must follow local regulations, if more stringent than regulations enforced by the CDC or the FDA. Do not pipette by mouth. To avoid cross-contamination, use separate transfer pipettes or tips for all materials. Do not use beyond the expiration date shown on the label. If product is received damaged or leaking, contact ZeptoMetrix LLC for instructions. 



    NOT FOR USE IN HUMANS: 

    These products are NOT intended for use in the manufacture or processing of injectable products subject to licensure under the USA Food and Drug Administration Section 351 of the Public Health Service Act or for any other product intended for administration to humans. 



    RECOMMENDED STORAGE: 

    NATtrol™ CT/NG Negative Controls should be stored at 2-8°C. When stored as directed, controls are suitable for use for up to 56 days (8 weeks) once opened. 



    INSTRUCTIONS FOR USE: 

    Vortex NATtrol™ CT/NG Negative Control vials for 10 seconds to mix. Follow the manufacturer instructions for use as a clinical sample. 



    LIMITATIONS:

    NATtrol™ CT/NG Negative Controls are USA FDA Class 1 exempt, unassayed, in vitro diagnostic external run controls and are intended for professional use only. NATtrol™ CT/NG Negative Controls are not intended for use as a substitute for the internal controls provided by in vitro diagnostic kit manufacturers. Quality control materials should be used in accordance with local, state, federal and accreditation requirements. 



    EXPECTED RESULTS: 

    One lot of NATtrol™ CT/NG Negative Control was tested in two separate labs on three different assays. Qualitative results are shown in Table 1. Product homogeneity has been demonstrated by validation studies and quality control testing. Each laboratory must evaluate the controls and establish their own acceptance criteria. The data shown below is for informational purposes only. 



    Table 1:

     

    *Not Tested


     

    ETIOLOGIC STATUS/BIOHAZARD TESTING: 

    The Purified Protein Matrix used in the manufacture of this product is treated with 0.09% sodium azide. It was manufactured from materials that have been tested and found non-reactive at the donor level for HIV-1/HIV-2 Antibody, HBsAg and HCV Antibody by FDA licensed donor screening test methods. All materials are also tested for HIV-1 and HCV by FDA approved Nucleic Acid Test (NAT) methods. Heat inactivated bovine based source materials used in the manufacture of this product meet applicable USDA requirements for abattoir sourced animals, traceability and country of origin. The materials were collected at USDA licensed establishments or legally imported from countries recognized by the USDA as negligible or controlled for risk for Bovine Spongiform Encephalopathy (BSE) and other exotic disease agents. Donor animals were inspected ante and post mortem at the abattoir as required by the USDA.